Beneath the Surface: Psoriatic Arthritis in Dermatology Practice—Simulations

The workshop included two case simulations. Each participant was asked to work on the simulations using a provided iPad®. In each simulation, participants explored a clinical vignette of a patient with psoriasis and psoriatic arthritis (PsA) and made a treatment decision choosing from the available options. Each case simulation was discussed with the entire group of participants. As part of the workshop, the multidisciplinary faculty team delivered three fast-paced, practice-oriented presentations. The first presentation reviewed the role of dermatology providers in PsA care, highlighting the importance of screening patients with psoriasis for PsA in order to timely diagnose PsA and start treatment that can prevent or reduce joint damage. The second presentation addressed the wide range of PsA therapies and latest evidence-based recommendations for treatment of PsA. The third presentation introduced an approach for patient-provider shared decision making in the treatment of psoriasis and PsA. Throughout the workshop, participants were invited to answer questions, as well as ask questions and make comments, verbally and via iPads.

Date: January 30, 2018 
Venue: Haleakala Ballroom 4/5, Grand Wailea Wailea, Hawaii

Review activity content under the Materials button (below).



Neil J. Korman, MD, PhD

Activity Chair,
Director, Clinical Trials Unit
Clinical Director, Murdough Family Center for Psoriasis
Professor, Dermatology
University Hospitals Cleveland Medical Center
Case Western Reserve University School of Medicine
Cleveland, Ohio

April W. Armstrong, MD, MPH

Associate Dean for Clinical Research
Associate Professor of Dermatology,
Director of Clinical Research, Clinical and Translational Science Institute,
Director of Clinical Trials and Outcomes Research,
Director of Psoriasis Program,
Department of Dermatology
Keck School of Medicine of USC
Los Angeles, California

Rebecca R. Muntean, MD, ND, FACR

Clinical Rheumatologist,
Providence Health & Services
University of Washington WWAMI Regional Medical Education
Providence Spokane Internal Medicine
Premier Clinical Research
Spokane, Washington

Learning Objectives

As a result of participation in this educational activity, participants should increase their ability to:

Screen patients with psoriasis for PsA at each visit.

Discuss Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) recommendations for treatment of PsA

Incorporate advances in treatment of PsA into care of patients with psoriasis and PsA to achieve desired treatment targets

Effectively engage patients with psoriasis and PsA in shared decision making regarding treatment goals, development of treatment plan, and treatment modification

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of this workshop.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative): Marianna Shershneva, MD, PhD and Christine Tebben

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Presenter: Neil J. Korman, MD, PhD, is an advisor for AbbVie Inc., Celgene Corporation, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., and Regeneron Pharmaceuticals, Inc.; investigator for AbbVie Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Pfizer Inc., and Regeneron Pharmaceuticals, Inc.; speaker for AbbVie Inc., Celgene Corporation, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., and Novartis; and consultant for Novartis and Pfizer Inc.
  • Presenter: April W. Armstrong, MD, MPH, is a consultant for Novartis, Sanofi, Regeneron, Pfizer, Celgene, Modernizing Medicine, AbbVie, Lilly, Merck, and Janssen; speaker and researcher for Lilly, AbbVie, and Janssen
  • Presenter: Rebecca R. Muntean MD, ND, FACR, is a speaker for Janssen

Activity Information

Target Audience
The target audience for this workshop was dermatologists. Other healthcare professionals, including rheumatologists, physician assistants, and nurse practitioners who treat patients with PsA, may have benefited from participation in this educational activity. 

Accreditation Statement
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Forefront Collaborative designated this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Content Review
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative or Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose. 

This continuing medical education activity included reference(s) to unlabeled or unapproved uses of drugs or devices.

This activity is provided by Forefront Collaborative.

Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit

Not Enrolled
This course is currently closed